EyePoint announces positive recommendation by Data Safety Monitoring Committee for phase 3 trials for Duravyu

Reuters
2025.11.19 12:17
Nov 19 (Reuters) - EyePoint Pharmaceuticals Inc (EYPT.O) : * EYEPOINT ANNOUNCES POSITIVE RECOMMENDATION FROM INDEPENDENT DATA SAFETY MONITORING COMMITTEE FOR PIVOTAL PHASE 3 TRIALS FOR DURAVYU™ IN WET AGE-RELATED MACULAR DEGENERATION * EYEPOINT PHARMACEUTICALS INC - TOPLINE DATA FOR LUGANO EXPECTED MID-2026 Source text: Further company coverage: (EYPT.O)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.